Food & Drug Administration (FDA) would disagree with DSIPs designation as incredibly safe, as the peptide is included on its list of bulk drug substances with significant safety risks
Even though it is not considered a fat-burning peptide, some researchers and healthcare providers believe it may indirectly support weight management through several mechanisms
Adverse effects of desmopressin Desmopressin is relatively safe for use in animals with central diabetes insipidus
Visible density improvements typically appear between months 3-6 of consistent use
Limitations: No joint-specific human RCTs
If a compounded product contains peptide fragments, impurities, aggregates, degradation products, or an incompletely characterised active ingredient, the immune system may recognise parts of that product as foreign